Alembic Pharmaceuticals Ltd - 533573 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report21/05/2019 3 Name of the Certifying Firm Samdani Shah & Kabra 4 Name of the Certifying Individual S. Samdani 5Membership TypeFCS 6 Membership Number 3677 7 CP No. 2863 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO Alembic Pharmaceuticals gets USFDA nod for over-active bladder treatment drug
The company said it now has a total of 94 ANDA approvals from the USFDA ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Solifenacin Succinate Tablets, 5 mg and 10 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 17th May, 2019. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or legal heir(s) of the registered shareholder(s) on 16th May, 2019. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s). Alembic Pharmaceuticals Ltd - 533573 - Board recommends Dividend
Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 08, 2019, inter alia, has recommended a dividend of Rs. 5.50/- (275%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. Alembic Pharmaceuticals Ltd - 533573 - Standalone & Consolidated Financial Results, Auditors Report, Results Press Release, Result Presentation for March 31, 2019
Alembic Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20192. Consolidated Financial Results for the period ended March 31, 20193. Standalone Auditors Report for the period ended March 31, 20194. Consolidated Auditors Report for the period ended March 31, 20195. Result Press Release for the period ended March 31, 20196. Result Presentation for the period ended March 31, 2019 Alembic Pharma inks pacts for market access in China
Vadodara-based Alembic Pharmaceuticals Ltd on Tuesday announced the signing of a joint venture agreement with SPH SINE Pharmaceutical Laboratories Co